Bioretec Ltd. announced that it has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland. The acquired machine is optimized for the production of magnesium-based implants and especially for the first product from the RemeOsTM product family, the RemeOsTM screw, which was granted market authorization in the U.S. in March 2023. The new CNC machining center will significantly increase the company's production capacity of RemeOs™ screws for the U.S. market.

The company estimate the commissioning of the machine to take place at the beginning of next year considering the current delivery time of 5-6 months. The addition of the company's own machining center for RemeOs™ products will also enhance the production of its Activa implants.